Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.
Hosted on MSN1d
GLP-1 Trends by CivicScience: GLP-1 Users Foresee Long-Term Use, Spending More on Clothing and Groceries, Plus MoreThis is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...
Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...
They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...
Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...
News Medical on MSN3d
High discontinuation rates of GLP-1 agonists found among patients with obesityDiscontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback